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INTRODUCTION
Toll-like receptors (TLRs) are evolution-
arily conserved pattern recognition mol-
ecules. Since the discovery of the Toll
pathway cascade (1, 2), our knowledge
about the structure, function, and mechan-
ics of TLRs in infectious and inflam-
matory conditions has increased remark-
ably. The role of TLR4 as a pathogen-
pattern recognition receptor has been
studied extensively. We now know that
TLR4 recognizes pathogen-associated mol-
ecular patterns (PAMPs), such as Gram-
negative bacterial lipopolysaccharide (LPS)
and endogenous damage-associated mol-
ecular patterns (DAMPs) like fibronectin
and hyaluronan, which are released during
infectious and non-infectious inflamma-
tory conditions. Some chronic infections
and inflammatory conditions are known
to promote carcinogenesis. For example,
Helicobacter pylori (3) and viral hepati-
tis (4) infections lead to gastric and liver
cancers, respectively. Also, in inflamma-
tory bowel disease, non-infectious inflam-
mation promotes the development of col-
orectal cancer (5). Evidence from recent
reports suggests that increased expression
and activity of TLR4 in chronic infectious
and inflammatory conditions is associated
with cancer progression (6–8). At the same
time, additional studies suggest the protec-
tive role of TLR4 in cancer (9–14). The
role of TLR4 in cancer has only recently
been studied. This review article provides a
brief summary of the current understand-
ing of TLR4-signaling, its pro- and anti-
cancer effects, and the therapeutic poten-
tial of TLR4 immunomodulation in the
prevention and treatment of cancer.
LIGAND RECOGNITION AND
ACTIVATION OF TLR4
Activation of TLR4 and downstream intra-
cellular signaling involves interaction with
TLR4 ligands, dimerization, and assembly
of the TLR4-complex with its adaptor and
co-receptor molecules. Our understanding
of TLR4-signaling is based on the results
of the studies focused on the interaction
of TLR4 with Escherichia coli-derived LPS.
It has been demonstrated that the LPS
binding protein (LBP) transfers the LPS
to CD14 that is present in soluble form
or linked to the cell surface by a glyco-
sylphosphatidylinositol anchor. LPS is then
transferred from CD14 to the myeloid dif-
ferentiation (MD2) protein (6). CD14 and
MD2 do not have cytoplasmic tails and are
unable to transduce signals on their own.
The fatty acyl chains of lipid A of LPS
are integrated into the hydrophobic pocket
of MD2, and negatively charged phos-
phate groups on the diglucosamine back-
bone of lipid A interact with the charged
residues at the opening of the binding
pocket of MD2. The LPS–MD2 interac-
tion with TLR4 then causes dimerization
of the TLR4–MD2 in 1:1 ratio and assem-
bly of TLR4–MD2–LPS complex. The crys-
tal structure of human TLR4–MD2–LPS
complex shows the formation of an “m”-
shaped oligomer made up of two molecules
of TLR4 and two molecules of MD2 (15).
Figure 1A provides a pictorial representa-
tion of the steps involved in the formation
of the TLR4–MD2–LPS complex.
TLR4-SIGNALING AND HOST DEFENSE
MECHANISMS
After the TLR4–MD2–LPS complex for-
mation, TLR4 signals through myeloid
differentiation primary response pro-
tein (MYD88)-dependent and Toll/IL-
1R domain-containing adaptor inducing
interferon-beta (TRIF)-dependent path-
ways. Dimerization of TLR4–MD2 recruits
TIRAP (Toll/IL-1R domain-containing
adaptor protein) and MYD88, leading
to intracellular signaling, activation of
transcription factors, and production of
pro-inflammatory cytokines. TLR4 also
recruits additional proteins, TRIF-related
adaptor molecule (TRAM) and TRIF, and
induces production of type I interfer-
ons. Type I interferons are associated with
immune responses elicited by T and NK
cells, important effector cells of adap-
tive immunity (16). During the late phase
of signaling, activation of TRIF can also
induce NF-κB transcription factor.
Immune response to any pathogenic
stimuli includes activation of innate immu-
nity, inflammation, and adaptive immu-
nity. TLR4-signaling can eventually lead
to a multitude of cellular effects (17). It
is well-established that during the innate
phase of immune response, TLR4 recog-
nizes its ligands (pathogens, PAMPs, or
DAMPs), and facilitates their uptake, intra-
cellular processing, and the inflammatory
response (18–21). After the TLR4 ligands
are internalized and processed, the anti-
gens are loaded onto the major histocom-
patibility complex (MHC) molecules for
presentation to naïve lymphocytes. Pub-
lished reports support the role of TLR4
in antigen-presentation and activation of
cellular and humoral immune responses
(22–25). Figure 1B summarizes the recog-
nition of ligands by TLR4, TLR4-signaling
through MYD88 and TRIF, and its role
in inflammation and antigen-presentation.
Thus, it is apparent that TLR4 is involved
directly or indirectly with different arms of
the host defense system (21, 26).
TLR4 AND CANCER
TLR4 is associated with cancer in several
ways. Diverse cell lines and tissue sam-
ples derived from patients with head and
neck, esophageal, gastric, colorectal, liver,
pancreatic, skin, breast, ovarian, cervical,
and breast cancer have been shown to
express increased amounts of TLR4 (27).
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FIGURE 1 | (A) A cartoon showing assembly of TLR4–MD2–LPS complex. The LPS is transferred to MD2 (i) Conjugation of LPS–MD2 with TLR4 (ii) then leads
to dimerization of TLR4–MD2, and formation of TLR4–MD2–LPS complex (iii). (B) After the recognition of ligand and assembly of TLR4-complex, co-receptors:
TIRAP, MYD88, TRAM and TRIF, are recruited at the intracellular level for activation of TLR4-signaling resulting into antigen-specific immune responses.
Constitutive expression of some TLR4
genetic variants has also been linked to
cancer (28–32). These characteristics are
therefore being considered for their prog-
nostic value in cancer treatment (32–34).
In these scenarios of established cancer,
TLR4 facilitates an environment that is
suitable for continued cancer cell pro-
liferation. Pro-cancer mechanisms could
include the evasion of cancer cells from
immune surveillance (35–38).
Persistent activation of TLR4-induced
inflammatory signaling in chronic inflam-
matory conditions can also contribute
to carcinogenesis (39). Experimental
evidence suggests that cancer cell migration
and invasion are induced by trigger-
ing of TLR4-NF-κB under inflammatory
conditions (40–42). LPS-induced TLR4-
signaling also promotes cancer cell survival
and proliferation in hepatocellular carci-
noma (43, 44). Moreover, the blockade
of TLR4 by siRNA and NF-κB inhibitors
decreases the invasive ability of cancer cells.
Correspondingly, TLR4 silencing has been
shown to decrease tumor burden in a
murine model of colorectal metastasis and
hepatic steatosis (45).
At the same time, published data sug-
gest that TLR4 is required for protec-
tive immune response and killing of can-
cer cells. For example, TLR4-deficient
mice developed more tumors after oral
gavage with polyaromatic hydrocarbon
7,12-dimethylbenz(a)anthracene than did
wild-type mice (46). Similarly, silencing
of TLR4 increased breast cancer metas-
tasis (47). Although mechanism is not
fully understood, TLR4 can induce an effi-
cient cancer antigen-specific cytotoxic T
cell immune response (48). The cytotoxic T
cells will eventually kill the cancer cells. The
dynamics of the TLR4-induced immune
parameters in the tumor microenviron-
ment could be complex, and is not well
studied. It is possible that TLR4 exerts
pro- or anti-cancer effects, depending on
the prevailing conditions in the tissue
microenvironment during different phases
of cancer development or metastasis.
CURRENTLY AVAILABLE TLR4
IMMUNOMODULATORY AGENTS
A number of immunomodulators, which
target TLR4 have been developed. These
modulators (antagonists or agonists) have
been grouped based on their binding and
sequestration of LPS, antagonizing LBP
and CD14/LPS interactions, and targeting
of MD2, TLR4–MD2, or TLR4.
Monophosphoryl lipid A (MPLA), a
chemically modified derivative of LPS,
is less toxic, and retains most of the
immunostimulatory activity of LPS. MPLA
serves as a TLR4 agonist. It has been
approved in Europe as a vaccine adju-
vant, and is a component of Hepati-
tis B and Human Papillomavirus Virus
vaccines (49). Another lipid-based ago-
nist, E6020 (Eisai/Sanofi Pasteur), has
also been developed as a vaccine adju-
vant (50, 51). Other lipid molecules
are being investigated for their poten-
tial to target the CD14–LPS interac-
tion and antagonistic activity (52). Eri-
toran (E5564), developed by Eisai (Tokyo,
Japan), directly binds to the hydropho-
bic pocket of MD2, competitively inhibits
LPS from binding to MD2, and pre-
vents the dimerization of TLR4, as well
as TLR4-signaling (53). TAK-242, a cyclo-
hexene derivative, was later developed by
Takeda Pharmaceuticals (Tokyo, Japan)
to target the TLR4 on the cellular
membrane. Both TAK-242 and Eritoran
(E5564) have been investigated in clini-
cal trials as possible treatments for sep-
sis (54). Ibudilast (AV4II), a TLR4 antag-
onist, has been shown to suppress pro-
inflammatory cytokines, such as TNF-α
and IL-6, in neuroinflammation (55). Anti-
bodies that target TLR4, NI-0101, and
IA6 (NovImmune, Geneva, Switzerland),
are being investigated for the treatment
of acute and chronic inflammation. Glu-
copyranosyl lipid adjuvant-stable emul-
sion (GLA-SE; Immune design, Seattle,
WA, USA), is also being studied (http://
www.clinicaltrials.gov). Although Eritoran
and TAK-242 did not show efficacy for
treatment of sepsis, a complicated clini-
cal problem, studies with these modulators
have clearly improved our understanding
of the structural aspects of TLR4-complex
formation and signaling.
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POTENTIAL OF TLR4
IMMUNOMODULATION FOR THE
PREVENTION OR TREATMENT OF
CANCER
Agents with TLR4-antagonistic activity
have been shown to reduce inflammation-
induced carcinogenesis by suppressing
the TLR4-induced NF-κB signaling. Cur-
cumin, the main constituent of the spice
turmeric, has been found to most likely
bind to MD2, thus competing with LPS
(56). A number of synthetic curcuminoids,
such as EF24, have also been found to have
anti-inflammatory activity (57–60). Our
lab recently developed TLR4-interacting
surfactant protein-A (SP-A) peptide, called
SPA4, which binds to TLR4 protein in
complex with MD2, and is effective ther-
apeutically in cell culture systems and in
a mouse model (61, 62). In the initial
studies, our results showed that the TLR4-
interacting SPA4 peptide suppresses LPS–
TLR4-induced migration and invasion of
colon cancer cells (63). More studies are
warranted to understand the mechanism of
SPA4 peptide activity. Other agents, includ-
ing resveratrol (64),NI-0101 antibody (65),
and paeoniflorin (66), have also shown
suppression of inflammation-induced car-
cinogenesis.
While TLR4 antagonists could help
reduce progression of inflammation-
induced carcinogenesis or metastasis,TLR4
agonists have been shown to induce anti-
tumor immunity in patients and mod-
els of established cancer. Lipid A-based
TLR4 agonists, known as OM-174 and
AS15, exhibit anti-cancer effects (67–70).
Incorporation of the LPS and E6020
to Paclitaxel, whole cell tumor cell vec-
tor, and Trastuzumab improved the anti-
tumor immunity in mouse models (71–
73). Picibanil (OK-432) targets both TLR2
and TLR4 and suppresses cancer (74).
Vacchelli et al. recently published a detailed
review of the ongoing clinical trials on
TLR modulators, including TLR4 agonists.
While the results from the ongoing clin-
ical trials are pending, there is currently
a significant emphasis on the design and
development of novel TLR4 immunomod-
ulators.
Although the potential of TLR4
immunomodulation for cancer immuno-
therapy has not been explored extensively,
initial results from pre-clinical and clinical
studies look promising. It is reasonable
to imagine a TLR4 immunomodulatory
agent that reduces inflammatory response,
but promotes anti-tumor immunity. This
could be beneficial in controlling mul-
tiple stages of cancer. Comprehensive
studies are therefore needed to under-
stand the mechanism of action of TLR4
immunomodulators in appropriate in vitro
and in vivo models of cancer.
INFORMATION ABOUT PATENT
APPLICATIONS PERTAINING TO TLR4
IMMUNOMODULATION BY
SURFACTANT PROTEIN-A (SP-A)
DERIVED PEPTIDES
Patent applications have been filed on the
concept of TLR4-interacting SP-A peptides
for immunomodulation with United States
Patent and Trademark Office (USPTO),
World Intellectual Property Organization,
European, Canadian, and Australian Patent
agencies. A patent was recently issued by
the USPTO (US 8,623,832; Inventor: Shan-
jana Awasthi; Assigned to the Board of
Regents of the University of Oklahoma,
Norman, Oklahoma).
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